Inhibition of DYRK1A attenuates vascular remodeling in pulmonary arterial hypertension via suppressing STAT3/Pim-1/NFAT pathway

References

• Boucherat O, Agrawal V, Lawrie A, Bonnet S. The latest in animal models of pulmonary hypertension and right ventricular failure. Circ Res. 2022;130(9):1466–10. doi: 10.1161/circresaha.121.319971. PubMed PMID: 35482834.
   PubMed Web of Science ®Google Scholar
• Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022;59(6). doi:10.1183/13993003.02334-2021. PubMed PMID: 34737219.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914. doi:10.1183/13993003.01914-2018. PubMed PMID: 30545980.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Ghofrani HA, Weissmann N, Aldashev A, Zhao L. Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation. 2015;131(6):582–90. doi:10.1161/circulationaha.114.006977. PubMed PMID: 25666980.
   PubMed Web of Science ®Google Scholar
• Calvier L, Boucher P, Herz J, Hansmann G. LRP1 deficiency in vascular SMC leads to pulmonary arterial hypertension that is reversed by PPARγ activation. Circ Res. 2019;124(12):1778–85. doi:10.1161/circresaha.119.315088. PubMed PMID: 31023188.
   PubMed Web of Science ®Google Scholar
• Laham AJ, Saber-Ayad M, El-Awady R. DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis. Cell Mol Life Sci. 2021;78(2):603–19. doi: 10.1007/s00018-020-03626-4. PubMed PMID: 32870330.
   PubMed Web of Science ®Google Scholar
• Jarhad DB, Mashelkar KK, Kim HR, Noh M, Jeong LS. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics. J Med Chem. 2018;61(22):9791–810. doi: 10.1021/acs.jmedchem.8b00185. PubMed PMID: 29985601.
   PubMed Web of Science ®Google Scholar
• Luna J, Boni J, Cuatrecasas M, Bofill-De Ros X, Núñez-Manchón E, Gironella M, Vaquero EC, Arbones ML, de la Luna S, Fillat C, et al. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut. 2019;68(8):1465–76. doi:10.1136/gutjnl-2018-316128. PubMed PMID: 30343272.
   PubMed Web of Science ®Google Scholar
• Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, Yip BH, Tsai Y-C, Jenni S, Bornhauser B, et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021;131(1). doi:10.1172/jci135937. PubMed PMID: 33393494.
   PubMed Web of Science ®Google Scholar
• Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, et al. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J Clin Invest. 2013;123(6):2475–87. doi:10.1172/jci63623. PubMed PMID: 23635774.
   PubMed Web of Science ®Google Scholar
• Wang P, Alvarez-Perez JC, Felsenfeld DP, Liu H, Sivendran S, Bender A, Kumar A, Sanchez R, Scott DK, Garcia-Ocaña A, et al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med. 2015;21(4):383–8. doi:10.1038/nm.3820. PubMed PMID: 25751815.
   PubMed Web of Science ®Google Scholar
• Ferron SR, Pozo N, Laguna A, Aranda S, Porlan E, Moreno M, Fillat C, de la Luna S, Sánchez P, Arbonés ML, et al. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell. 2010;7(3):367–79. doi:10.1016/j.stem.2010.06.021. PubMed PMID: 20804972.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Lee JG, Kim JH, Kim SY, Huh YH, Kim HJ, Lee K-S, Yu K, Lee J-S. Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish. Dis Model Mech. 2019;12(5): PubMed PMID: 31043432. doi:10.1242/dmm.037044.
   Web of Science ®Google Scholar
• Kuhn C, Frank D, Will R, Jaschinski C, Frauen R, Katus HA, Frey N. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem. 2009;284(25):17320–27. doi: 10.1074/jbc.M109.006759. PubMed PMID: 19372220.
   PubMed Web of Science ®Google Scholar
• Young A, Bradley LA, Farrar E, Bilcheck HO, Tkachenko S, Saucerman JJ, Bekiranov S, Wolf MJ. Inhibition of DYRK1a enhances cardiomyocyte cycling after myocardial infarction. Circ Res. 2022;130(9):1345–61. doi: 10.1161/circresaha.121.320005. PubMed PMID: 35369706.
   PubMed Web of Science ®Google Scholar
• Lan C, Chen C, Qu S, Cao N, Luo H, Yu C, Wang N, Xue Y, Xia X, Fan C, et al. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. EBioMedicine. 2022;82:104139. PubMed PMID: 35810562. doi:10.1016/j.ebiom.2022.104139.
   PubMed Web of Science ®Google Scholar
• Abbassi R, Johns TG, Kassiou M, Munoz L. DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications. Pharmacol Therapeut. 2015;151:87–98. doi:10.1016/j.pharmthera.2015.03.004. PubMed PMID: 25795597.
   PubMed Web of Science ®Google Scholar
• Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulat. 2011;123(11):1205–15. doi:10.1161/circulationaha.110.963314. PubMed PMID: 21382889.
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell. 1999;98(3):295–303. doi: 10.1016/s0092-8674(00)81959-5. PubMed PMID: 10458605.
   PubMed Web of Science ®Google Scholar
• Murugesan P, Zhang Y, Youn JY, Cai H. Novel and robust treatment of pulmonary hypertension with netrin-1 and netrin-1-derived small peptides. Redox Biol. 2022;55:102348. doi:10.1016/j.redox.2022.102348. PubMed PMID: 35830752.
   PubMed Web of Science ®Google Scholar
• Liu B, Peng Y, Yi D, Machireddy N, Dong D, Ramirez K, Dai J, Vanderpool R, Zhu MM, Dai Z, et al. Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension. Eur Respir J. 2022;60(6):2102643. doi:10.1183/13993003.02643-2021. PubMed PMID: 35798360.
   PubMed Web of Science ®Google Scholar
• Veith C, Vartürk-Özcan I, Wujak M, Hadzic S, Wu CY, Knoepp F, Kraut S, Petrovic A, Gredic M, Pak O, et al. SPARC, a novel regulator of vascular cell function in pulmonary hypertension. Circulation. 2022;145(12):916–33. doi:10.1161/circulationaha.121.057001. PubMed PMID: 35175782.
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Sweatt AJ, Maron BA. Harnessing big data to advance treatment and understanding of pulmonary hypertension. Circ Res. 2022;130(9):1423–44. doi: 10.1161/circresaha.121.319969. PubMed PMID: 35482840.
   PubMed Web of Science ®Google Scholar
• Jin Q, Guan L, Pan W, Zhou D. Initial triple combination therapy for intermediate-and high-risk pulmonary arterial hypertension: standard of care or still too soon to tell? Am J Respir Crit Care Med. 2021;204(12):1491–2. doi:10.1164/rccm.202107-1622LE. PubMed PMID: 34672865.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods. 2005;2(1):17–25. doi:10.1038/nmeth731. PubMed PMID: 15789031.
   PubMed Web of Science ®Google Scholar
• Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780–9. doi: 10.1172/jci76094. PubMed PMID: 25932675.
   PubMed Web of Science ®Google Scholar
• Liu T, Wang Y, Wang J, Ren C, Chen H, Zhang J. DYRK1A inhibitors for disease therapy: current status and perspectives. Eur J Med Chem. 2022;229:114062. doi:10.1016/j.ejmech.2021.114062. PubMed PMID: 34954592.
   PubMed Web of Science ®Google Scholar
• Rammohan M, Harris E, Bhansali RS, Zhao E, Li LS, Crispino JD. The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target. Oncogene. 2022;41(14):2003–11. doi:10.1038/s41388-022-02245-6. PubMed PMID: 35220406.
   PubMed Web of Science ®Google Scholar
• Stotani S, Giordanetto F, Medda F. DYRK1A inhibition as potential treatment for Alzheimer’s disease. Future Med Chem. 2016;8(6):681–96. doi:10.4155/fmc-2016-0013. PubMed PMID: 27073990.
   PubMed Web of Science ®Google Scholar
• Barzowska A, Pucelik B, Pustelny K, Matsuda A, Martyniak A, Stępniewski J, Maksymiuk A, Dawidowski M, Rothweiler U, Dulak J, et al. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis. Cells. 2021;10(9):2263. doi:10.3390/cells10092263. PubMed PMID: 34571911.
   PubMed Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski A, Pullamsetti SS, Schermuly RT, Stenmark K, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887. doi:10.1183/13993003.01887-2018. PubMed PMID: 30545970.
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Frid MG, Graham BB, Tuder RM. Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension. Cardiovasc Res. 2018;114(4):551–64. doi:10.1093/cvr/cvy004. PubMed PMID: 29385432.
   PubMed Web of Science ®Google Scholar
• Fan Y, Gu X, Zhang J, Sinn K, Klepetko W, Wu N, Foris V, Solymosi P, Kwapiszewska G, Kuebler WM, et al. TWIST1 drives smooth muscle cell proliferation in pulmonary hypertension via loss of GATA-6 and BMPR2. Am J Respir Crit Care Med. 2020;202(9):1283–96. doi:10.1164/rccm.201909-1884OC. PubMed PMID: 32692930.
   PubMed Web of Science ®Google Scholar
• Amsellem V, Lipskaia L, Abid S, Poupel L, Houssaini A, Quarck R, Marcos E, Mouraret N, Parpaleix A, Bobe R, et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation. 2014;130(11):880–91. doi:10.1161/circulationaha.114.010757. PubMed PMID: 24993099.
   PubMed Web of Science ®Google Scholar
• Mouraret N, Houssaïni A, Abid S, Quarck R, Marcos E, Parpaleix A, Gary-Bobo G, Dubois-Randé JL, Derumeaux G, Boczkowski J, et al. Role for telomerase in pulmonary hypertension. Circulation. 2015;131(8):742–55. doi:10.1161/circulationaha.114.013258. PubMed PMID: 25550449.
   PubMed Web of Science ®Google Scholar
• Parpaleix A, Amsellem V, Houssaini A, Abid S, Breau M, Marcos E, Sawaki D, Delcroix M, Quarck R, Maillard A, et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. Eur Respir J. 2016;48(2):470–83. doi:10.1183/13993003.01448-2015. PubMed PMID: 27418552.
   PubMed Web of Science ®Google Scholar
• Wei R, Lv X, Fang C, Liu C, Ma Z, Liu K, Zhou R. Silencing TUFM inhibits development of monocrotaline-induced pulmonary hypertension by regulating mitochondrial autophagy via AMPK/mTOR Signal pathway. Oxid Med Cell Longev. 2022;2022:1–16. doi:10.1155/2022/4931611. PubMed PMID: 35936222.
   Web of Science ®Google Scholar
• Kay LJ, Smulders-Srinivasan TK, Soundararajan M. Understanding the multifaceted role of human down syndrome kinase DYRK1A. Adv Protein Chem Struct Biol. 2016;105:127–71. doi:10.1016/bs.apcsb.2016.07.001. PubMed PMID: 27567487.
   PubMed Web of Science ®Google Scholar
• Lin TE, Chao MW, HuangFu WC, Tu HJ, Peng ZX, Su CJ, Sung T-Y, Hsieh J-H, Lee C-C, Yang C-R, et al. Identification and analysis of a selective DYRK1A inhibitor. Biomed Pharmacother. 2022;146:112580. doi:10.1016/j.biopha.2021.112580. PubMed PMID: 34968920.
   PubMed Web of Science ®Google Scholar
• Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay È, Lambert C, Jacob MH, Bonnet SN, et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012;40(3):618–29. doi:10.1183/09031936.00084211. PubMed PMID: 22496325.
   PubMed Web of Science ®Google Scholar